GAITHERSBURG, MD, May 17, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision bacteriophage (“phage”) therapy in patients with Diabetic Foot Osteomyelitis (DFO). Traditional […]
Rob Cohen
Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical Operations
GAITHERSBURG, MD, April 26, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Rob Casper as Vice President of Clinical Operations. Mr. Casper will oversee execution of global clinical trials of APT’s phage bank therapy. “I am pleased to welcome […]
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
–New funding follows initial Series B closing in May 2021– –Funding will be used to accelerate clinical trials against Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO) – GAITHERSBURG, MD, April 4, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that […]
Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study
GAITHERSBURG, MD, November 2, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support a multi-center Phase 1b/2, randomized, double-blind, placebo-controlled trial assessing the safety and microbiological activity of a single […]
Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
-Additional award brings APT’s total funding from the U.S. Department of Defense to $31.2 million– –Will support APT’s phage bankTM clinical stage programs targeting infectious diseases- GAITHERSBURG, MD, September 30, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the Department of Defense (DoD) has awarded the company […]
Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer
GAITHERSBURG, MD, September 23, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry. “We’re thrilled […]
Adaptive Phage Therapeutics Adds Jesse L. Goodman, M.D., M.P.H., to its Board of Directors
GAITHERSBURG, MD, September 14, 2021 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Jesse L. Goodman, MD, MPH, to the company’s Board of Directors. “Jesse has already made significant contributions to APT as an advisor and, as such, we are thrilled to have […]
Adaptive Phage Therapeutics Highlights the Publication of a Case Study of Investigational Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a Child
7-year-old child acquired antibiotic-resistant chronic Pseudomonas aeruginosa infection of her lower leg following injury sustained in a car accident Prior surgical debridement, hardware removal and three months of IV antibiotics had failed to stop the progress of infection – no other medical or surgical options were available. Pain-free weight bearing on the affected leg was achieved for […]
Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
– License to expanding phage library compiled at the Walter Reed Army Institute of Research – – Adaptive Phage Therapeutics is now engaged with two branches of the U.S. Military – GAITHERSBURG, MD., August 31, 2021 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has […]
Adaptive Phage Therapeutics to Present at the FDA and NIH Hosted Workshop on Science and Regulation of Bacteriophage Therapy
GAITHERSBURG, MD, August 24, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that Robert Hopkins, MD, Chief Medical Officer, will present at the upcoming Science and Regulation of Bacteriophage Therapy Workshop, hosted by the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and […]